Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Sebastian

Showing results (161-170 of 183) with videos related to

Pageof 19
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 14, 2023
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung CancerPhilip Bischoff, Martin Reck, Tobias Overbeck, et al.
Journal for Immunotherapy of Cancer|February 10, 2019
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancerAlexandros Papachristofilou, Madeleine M Hipp, Ute Klinkhardt, et al.
Lung Cancer (Amsterdam, Netherlands)|May 29, 2021
Corrigendum to "Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)" [Lung Cancer 152 (2021) 174-184]Frank Griesinger, Wilfried Eberhardt, Arnd Nusch, et al.
Lung Cancer (Amsterdam, Netherlands)|December 28, 2020
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)Frank Griesinger, Wilfried Eberhardt, Arnd Nusch, et al.
JCO Global Oncology|September 8, 2020
Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to ArmsKamal S Saini, Begoña de Las Heras, Ruth Plummer, et al.
Science (New York, N.Y.)|October 21, 2020
Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivityLudovico Cantuti-Castelvetri, Ravi Ojha, Liliana D Pedro, et al.
Clinical Lung Cancer|August 17, 2024
Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients With Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy After EGFR InhibitionFabian Acker, Alexandra Klein, Anna Rasokat, et al.
The Lancet. Respiratory Medicine|December 24, 2023
Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicineSara Cajander, Matthijs Kox, Brendon P Scicluna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2023
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in <i>NRAS</i>-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label StudyFilippo de Braud, Christophe Dooms, Rebecca S Heist, et al.
The Lancet. Oncology|January 16, 2015
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsJames Chih-Hsin Yang, Yi-Long Wu, Martin Schuler, et al.
Pageof 19

Showing results (161-170 of 183) with videos related to

Sort By:
Pageof 19
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 14, 2023
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung CancerPhilip Bischoff, Martin Reck, Tobias Overbeck, et al.
Journal for Immunotherapy of Cancer|February 10, 2019
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancerAlexandros Papachristofilou, Madeleine M Hipp, Ute Klinkhardt, et al.
Lung Cancer (Amsterdam, Netherlands)|May 29, 2021
Corrigendum to "Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)" [Lung Cancer 152 (2021) 174-184]Frank Griesinger, Wilfried Eberhardt, Arnd Nusch, et al.
Lung Cancer (Amsterdam, Netherlands)|December 28, 2020
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)Frank Griesinger, Wilfried Eberhardt, Arnd Nusch, et al.
JCO Global Oncology|September 8, 2020
Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to ArmsKamal S Saini, Begoña de Las Heras, Ruth Plummer, et al.
Science (New York, N.Y.)|October 21, 2020
Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivityLudovico Cantuti-Castelvetri, Ravi Ojha, Liliana D Pedro, et al.
Clinical Lung Cancer|August 17, 2024
Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients With Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy After EGFR InhibitionFabian Acker, Alexandra Klein, Anna Rasokat, et al.
The Lancet. Respiratory Medicine|December 24, 2023
Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicineSara Cajander, Matthijs Kox, Brendon P Scicluna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2023
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in <i>NRAS</i>-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label StudyFilippo de Braud, Christophe Dooms, Rebecca S Heist, et al.
The Lancet. Oncology|January 16, 2015
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsJames Chih-Hsin Yang, Yi-Long Wu, Martin Schuler, et al.
Pageof 19